Schwab U.S. Dividend Equity ETF (SCHD) Sees $679M Inflows Amid Strong Performance
The Schwab U.S. Dividend Equity ETF (SCHD) attracted over $679 million in inflows as its share price rose by 2.39% across five trading days, driven largely by strong performance from key holdings such as Merck, Abbott, and Amgen. Recent developments including positive clinical trial results for Merck’s cancer vaccine with Moderna and upgrades from major banks like Morgan Stanley contributed to the momentum in dividend-focused stocks. The fund's March 2026 reconstitution reshaped its portfolio by adding high-profile companies such as UnitedHealth Group, Procter & Gamble, Qualcomm, and Accenture while reducing energy exposure. Healthcare now accounts for over 21% of assets, with technology rising to nearly 8.75%. This shift reflects a broader market rotation toward defensive dividend payers amid the Federal Reserve's pause on rate hikes. SCHD has outperformed the S&P 500 by more than 18 percentage points year-to-date through August 21, reversing years of underperformance and signaling growing investor confidence in stable income-generating equities.
Tickers: $ABBV $ABT $ACN $AMGN $MRK $MRNA $PG $QCOM $SCHD $UNH